Tumor response assessment in patients by ICR across analyses from Study 15401,3,5,6

Response rates in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation1

Tumor response assessment in patients by ICR across analysis from clinical study 1540
  • Response rates are based on analysis by independent central review of Study 1540 at time of data cutoff.
  • CI=confidence interval; CR=complete response; CSCC=cutaneous squamous cell carcinoma; ICR=independent central review; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC; ORR=objective response rate; PR=partial response; Q2W=every 2 weeks; Q3W=every 3 weeks.

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1